Expert Interview
Discussing the potential of Bavarian Nordic's CHIKV VLP (PXVX0317), a virus-like particle (VLP)-based chikungunya virus vaccine candidate with a biochemist
Ticker(s): BVNRYInstitution: Albert Einstein College of Medicine
- Dan Danciger Professor of Biochemistry at Albert Einstein College of Medicine
- Research interest in application of peptide, protein and antibody engineering methods for the discovery and development of novel immunotherapies and vaccines.
- His lab has worked on many viruses including filoviruses (Ebola and Marburg virus), flaviviruses (Dengue and Zika virus), and alphaviruses (Chikungunya and Mayaro virus).
Can you talk about what a VLP-based vaccine is and how it could be utilized for the chikungunya virus?
Added By: sara_adminAre there any other chikungunya virus vaccine candidates you are familiar with?
Added By: sara_adminHow would you rate your level of excitement on a scale from 1 to 10 about PXVX0317?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
